English

In this webinar, CDC and HRSA speakers review the calendar year 2027–2031 Integrated HIV Prevention & Care Plan Guidance—highlighting key updates, submission requirements, and real-world recipient examples. The training equips CDC- and HRSA-funded jurisdictions with technical support, planning tools, and strategies to develop coordinated HIV prevention and care efforts by the June 30, 2026 deadline.

This guideline compiles up-to-date legal requirements across all U.S. states and territories, clarifying when healthcare providers and laboratories must report negative Hepatitis C test outcomes. It offers a clear, state-by-state breakdown to help public health entities and providers comply with surveillance obligations and improve data completeness.

This guideline presents a comprehensive state-by-state legal analysis of obligations for healthcare providers and laboratories to report negative HIV test outcomes. It clearly highlights jurisdictional differences, helping public health officials and clinicians ensure compliance with surveillance mandates and improve disease tracking.

GLP-1 receptor agonists (GLP-1s), including semaglutide, tirzepatide, and liraglutide, are increasingly used for weight management and show promise for people living with HIV (PLWH). While these medications are generally safe, PLWH may face additional considerations when using them due to how GLP-1s function and interact with antiretroviral therapy (ART). GLP-1s slow gastric emptying and suppress appetite, which may affect ART absorption; gastrointestinal side effects such as nausea or vomiting may also interfere with consistent ART dosing.

This infographic from Fair Health draws on data from its NPIC database—over 47 billion commercial medical and dental claims—to highlight rising trends in sexually transmitted disease (STD) diagnoses across various demographics in the U.S. between 2020 and 2023. The visuals show that overall STD diagnoses increased significantly, led by notable rises in syphilis, gonorrhea, and HIV/AIDS.

Tuberculosis (TB) remains the world’s deadliest infectious disease and a major treatment challenge, especially in cases resistant to standard therapies. A new AI-powered tool developed by Tufts University researchers, called DECIPHAER (Decoding Cross-Modal Information of Pharmacologies via Autoencoders), seeks to advance TB treatment by elucidating exactly how drugs kill the bacterium at the cellular and molecular levels.

Tuberculosis (TB), a contagious bacterial infection primarily affecting the lungs, remains a health risk in the U.S. Though cases declined for decades, recent increases — including ~10,347 cases in early data from 2024 — suggest testing and treatment of latent TB is needed more than ever.  Testing is crucial both for diagnosing latent TB (where bacteria are present but symptoms are absent) and active TB disease (which is contagious and manifests symptoms).

Syphilis remains a persistent sexually transmitted infection that requires rigorous diagnosis and management to prevent transmission, progression, and severe complications. This guideline distilled by Praxis Medical Insights outlines the current consensus from the Centers for Disease Control and Prevention (CDC) and related professional bodies on optimal screening methods, diagnostic interpretations, and treatment regimens.

Human papillomavirus (HPV) infects nearly 80% of people at some point during their lives, and while the immune system clears most infections, persistent HPV can lead to genital warts and several cancers (cervical, anal, vulvar, vaginal, penile, and oropharyngeal). HPV vaccination offers strong protection—preventing more than 90% of HPV-related cancers—and is most effective when administered before HPV exposure.

The webpage highlights the disproportionate rates of Hepatitis C virus among American Indian/ Alaska Native communities. This webpage highlights the Cherokee National Health Services acute Hepatitis C virus (HCV) elimination program, which provides community based testing at food distribution centers, universal screening, and rapid point of care diagnostics. Programs such as HCV and Linkage to Program (HELP) use telehealth to connect patients with providers. Project ECHO builds clinical capacity for local practitioners.